Bayer Submits New Drug Application for Radium (ra-223 Dichloride) for the Treatment of Castration- Resistant Prostate Cancer (crpc) with Bone Metastases
نویسنده
چکیده
Radium-223 (proposed trade name Alpharadin) was granted fast track designation by the FDA. The fast track process is designed to facilitate the development and expedited review of drugs to treat serious diseases and fill an unmet medical need. Fast track designation must be requested by the drug company and can be initiated at any time during the drug development process. (Continued on page 5) UPDATED TOOL NOW AVAILABLE TO PREDICT PROSTATE CANCER SPREAD
منابع مشابه
Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223
A 76-year-old man with symptomatic bone metastases from castrationresistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostate-specific antigen (PSA), doubling every month during Ra-223 therapy, suggested a PSA flare or rel...
متن کاملRadium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
INTRODUCTION Approximately 10 - 20% of prostate cancer cases ultimately progress to castration-resistant prostate cancer (CRPC), for which there is a poor prognosis and a therapeutic need. Radium-223 dichloride (radium-223 [Xofigo]) is a first-in-class α-emitting radiopharmaceutical shown to significantly prolong overall survival in patients with CRPC with symptomatic bone metastases and no vis...
متن کاملThe safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
INTRODUCTION A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for men with CRPC. The α-emitting radiopharmaceutical radium-223 dichloride has been shown to improve overall survival, time to symptomatic skeletal events (SSEs) and quality of life in CR...
متن کاملRadium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
© 2015 Harborside Press® In the United States, prostate cancer is the most common cancer and second leading cause of cancer-related deaths in men. It is estimated that 220,800 new cases of prostate cancer will have been diagnosed in 2015, with an estimated 27,540 deaths (American Cancer Society, 2015). Although prostate cancer is typically diagnosed when it is localized and considered curable, ...
متن کاملNursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
BACKGROUND Radium-223 dichloride, or radium-223, is a first-in-class alpha emitter that selectively targets bone metastases with high-energy, short-range alpha particles and is approved for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. Nurses are essential in educating patients about radium-223....
متن کامل